Opus Genetics, Inc.
OPGx-LCA5
Leber Congenital Amaurosis (LCA) due to biallelic mutations in the LCA5 gene
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for OPGx-LCA5 in Leber Congenital Amaurosis (LCA) due to biallelic mutations in the LCA5 gene are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Dosing with OPGx-LCA5 in the Phase 3 trial expected in the second half of 2026.”